Cixutumumab

Kevin P. McKian, Paul Haluska

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The IGF pathway plays a major role in cancer cell proliferation, survival and resistance to antineoplastic therapies in many human malignancies. As such, interference with this pathway is the target of many investigational pharmacologic agents. Cixutumumab, a monoclonal antibody to IGF-1R, utilizes this concept. In this review, we summarize preclinical, pharmacologic and early clinical data regarding this agent and discuss the impact this drug might have on the future treatment of human cancers.

Original languageEnglish (US)
Pages (from-to)1025-1033
Number of pages9
JournalExpert Opinion on Investigational Drugs
Volume18
Issue number7
DOIs
StatePublished - Jul 2009

Fingerprint

Neoplasms
Antineoplastic Agents
Cell Survival
Monoclonal Antibodies
Cell Proliferation
Pharmaceutical Preparations
anti-IGF-1R antibody A12
Therapeutics

Keywords

  • Cixutumumab
  • IGF-1R
  • IMC-A12
  • Monoclonal antibody

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Cixutumumab. / McKian, Kevin P.; Haluska, Paul.

In: Expert Opinion on Investigational Drugs, Vol. 18, No. 7, 07.2009, p. 1025-1033.

Research output: Contribution to journalArticle

McKian, KP & Haluska, P 2009, 'Cixutumumab', Expert Opinion on Investigational Drugs, vol. 18, no. 7, pp. 1025-1033. https://doi.org/10.1517/13543780903055049
McKian, Kevin P. ; Haluska, Paul. / Cixutumumab. In: Expert Opinion on Investigational Drugs. 2009 ; Vol. 18, No. 7. pp. 1025-1033.
@article{ebb91ddae85a497ea81f5b2ec7e727f2,
title = "Cixutumumab",
abstract = "The IGF pathway plays a major role in cancer cell proliferation, survival and resistance to antineoplastic therapies in many human malignancies. As such, interference with this pathway is the target of many investigational pharmacologic agents. Cixutumumab, a monoclonal antibody to IGF-1R, utilizes this concept. In this review, we summarize preclinical, pharmacologic and early clinical data regarding this agent and discuss the impact this drug might have on the future treatment of human cancers.",
keywords = "Cixutumumab, IGF-1R, IMC-A12, Monoclonal antibody",
author = "McKian, {Kevin P.} and Paul Haluska",
year = "2009",
month = "7",
doi = "10.1517/13543780903055049",
language = "English (US)",
volume = "18",
pages = "1025--1033",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Cixutumumab

AU - McKian, Kevin P.

AU - Haluska, Paul

PY - 2009/7

Y1 - 2009/7

N2 - The IGF pathway plays a major role in cancer cell proliferation, survival and resistance to antineoplastic therapies in many human malignancies. As such, interference with this pathway is the target of many investigational pharmacologic agents. Cixutumumab, a monoclonal antibody to IGF-1R, utilizes this concept. In this review, we summarize preclinical, pharmacologic and early clinical data regarding this agent and discuss the impact this drug might have on the future treatment of human cancers.

AB - The IGF pathway plays a major role in cancer cell proliferation, survival and resistance to antineoplastic therapies in many human malignancies. As such, interference with this pathway is the target of many investigational pharmacologic agents. Cixutumumab, a monoclonal antibody to IGF-1R, utilizes this concept. In this review, we summarize preclinical, pharmacologic and early clinical data regarding this agent and discuss the impact this drug might have on the future treatment of human cancers.

KW - Cixutumumab

KW - IGF-1R

KW - IMC-A12

KW - Monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=67650436410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650436410&partnerID=8YFLogxK

U2 - 10.1517/13543780903055049

DO - 10.1517/13543780903055049

M3 - Article

C2 - 19548856

AN - SCOPUS:67650436410

VL - 18

SP - 1025

EP - 1033

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 7

ER -